Dublin, Feb. 10, 2025 (GLOBE NEWSWIRE) — The “Doxorubicin – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering.
The global market for Doxorubicin was valued at US$1.2 Billion in 2024 and is projected to reach US$1.7 Billion by 2030, growing at a CAGR of 5.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers and forecasts.
Global Doxorubicin Market – Key Trends & Drivers Summarized
Doxorubicin is a potent chemotherapy drug commonly used to treat various types of cancer, including breast cancer, bladder cancer, Kaposi’s sarcoma, lymphoma, and acute lymphoblastic leukemia. Discovered in the 1960s, doxorubicin belongs to the anthracycline class of drugs, which work by intercalating DNA strands and inhibiting the enzyme topoisomerase II. This action prevents the replication of cancer cells, leading to their death. Doxorubicin is typically administered intravenously and is known for its distinctive red color, earning it the nickname ‘Red Devil’ due to its potent effects and significant side effect profile. Despite its efficacy, the use of doxorubicin is limited by its cardiotoxicity, which can lead to irreversible heart damage if not carefully monitored and managed.
The formulation and delivery methods of doxorubicin have seen significant advancements aimed at enhancing its therapeutic index and reducing its toxic side effects. One of the major breakthroughs in this area is the development of liposomal doxorubicin, which encapsulates the drug in liposomes, allowing for more targeted delivery to tumor cells while sparing healthy tissues. This modification has been shown to reduce cardiotoxicity and other systemic side effects, making treatment more tolerable for patients. Additionally, ongoing research is exploring the use of nanoparticles and other novel drug delivery systems to further improve the specificity and efficacy of doxorubicin. Advances in precision medicine are also paving the way for personalized dosing regimens based on individual patient profiles, aiming to maximize therapeutic outcomes while minimizing adverse effects.
The growth in the doxorubicin market is driven by several factors. The increasing incidence of cancer globally is a significant driver, as more patients require effective chemotherapeutic options. Advances in drug delivery technologies, such as liposomal formulations and nanoparticles, are enhancing the efficacy and safety profile of doxorubicin, encouraging its wider adoption. Furthermore, the expanding field of precision medicine is supporting the development of more tailored treatment regimens, potentially increasing the use of doxorubicin in combination therapies. Pharmaceutical companies are also investing heavily in research and development to explore new indications and combination treatments involving doxorubicin.
Additionally, improvements in healthcare infrastructure and increased access to cancer treatment in emerging markets are boosting the demand for effective chemotherapy agents. These factors collectively underscore the dynamic and evolving nature of the doxorubicin market, driven by technological advancements, rising cancer prevalence, and ongoing research efforts.
Scope of the Study
The report analyzes the Doxorubicin market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.
Segments:
- Application (Breast Cancer, Lung Cancer, Ovarian Cancer, Multiple Myeloma, Liver Cancer, Leukemia, Kaposi Sarcoma, Other Applications)
Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Breast Cancer Application segment, which is expected to reach US$374.1 Million by 2030 with a CAGR of a 5.6%. The Lung Cancer Application segment is also set to grow at 7.4% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $497.1 Million in 2024, and China, forecasted to grow at an impressive 8.0% CAGR to reach $145.0 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Merck, Glenmark Pharmaceuticals Ltd., Fresenius Kabi, Fresenius, Natco Pharma, Meiji Holdings, Celsion, MicroBiopharm Japan and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Key Questions Answered:
- How is the Global Doxorubicin Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 59 major companies featured in this Doxorubicin market report include:
- Merck
- Glenmark Pharmaceuticals
- Fresenius Kabi AG
- Fresenius
- Natco Pharma
- Meiji Holdings
- Celsion Corporation
- Health Biotech
- MicroBiopharm Japan Co., Ltd.
- Accord Healthcare Ltd.
- Olon
- Seqens
- Biovencer Healthcare
- Avacta Group
- CSPC Pharmaceutical Group
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 288 |
| Forecast Period | 2024 – 2030 |
| Estimated Market Value (USD) in 2024 | $1.2 Billion |
| Forecasted Market Value (USD) by 2030 | $1.7 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
Key Topics Covered:
MARKET OVERVIEW
- Doxorubicin – Global Key Competitors Percentage Market Share in 2024
- Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2024
- Cancer – An Insight
- Cancer Treatment
- Chemotherapy: An Overview
- An Introduction to Doxorubicin
- Global Doxorubicin Market Set to Witness Rapid Growth
- US Dominates the Doxorubicin Market, Asia-Pacific to Witness Fastest Growth
- Breast Cancer Constitutes the Largest Application for Doxorubicin
- Competition
- New Entrants Seek Opportunities
- Recent Market Activity
MARKET TRENDS & DRIVERS
- Rise in Cancer Incidence to Drive Market Growth
- Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
- Liposomal Delivery Systems Offer Significant Benefits
- A Review of Liposomal-Doxorubicin Preparations
- DOX Hydrochloride
- Ageing Demographics to Drive Demand
- Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
- Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
- Market to Gain from Rise in Number of Breast Cancer Cases
- Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Doxorubicin
- Age-Standardized Lung Cancer Rates for Select Countries
- Lymphoma, Leukemia, Bladder Cancer, & Kaposi Sarcoma: Other Major Growth Areas
- Uptrend in Healthcare Spending Drives the Doxorubicin Demand
- World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
- Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
- Cancer Research Spending Continues to Witness Growth
- A Netherlands Based Research Team Suggests a Variant of Doxorubicin can be Made more Effective without the Heart Damage Side Effect
- Researchers Develop Non-Toxic and Precise Nanoscale Technology for Oncology Drug Delivery
- Studies Show Positive Effect of Quantum Dot Enabled Doxorubicin Delivery in Lung Cancer Treatment
- Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
- Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Doxorucibin
- Combination Therapy: A Double Whammy Success
For more information about this report visit https://www.researchandmarkets.com/r/psoj56
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
